C-peptide (connecting peptide) has emerged as a critical biomarker in endocrinology, offering clinicians and researchers a reliable window into pancreatic beta-cell function and endogenous insulin secretion. Unlike insulin, which is rapidly cleared by the liver, C-peptide has a longer half-life and is excreted primarily by the kidneys, making it a stable and informative analyte. Over the past two decades, growing evidence has also revealed that C-peptide is not merely an inert byproduct of insulin synthesis—it exerts direct biological effects on vascular, neural, and renal tissues. This article provides a comprehensive, evidence-based exploration of C-peptide, from its molecular biology and physiological roles to its clinical utility in diagnosing and managing diabetes and other metabolic disorders, as well as its emerging therapeutic potential.

What Is C‑Peptide? Molecular Biology and Biochemistry

C‑peptide is a 31‑amino‑acid peptide that is cleaved from proinsulin during the maturation of insulin in the pancreatic beta‑cells. Proinsulin consists of three segments: the A‑chain, the B‑chain, and the connecting C‑peptide. After enzymatic processing by prohormone convertases (PC1 and PC2) and carboxypeptidase E, insulin and C‑peptide are released into the portal circulation in equimolar amounts. This stoichiometric relationship is the foundation for using C‑peptide as a surrogate marker of endogenous insulin secretion.

The stability of C‑peptide in blood (half‑life approximately 20–30 minutes) contrasts with insulin (half‑life 4–6 minutes), which is subject to significant hepatic first‑pass extraction. Moreover, C‑peptide is eliminated almost entirely by glomerular filtration, with little or no tubular reabsorption, enabling precise urinary measurements. These pharmacokinetic properties make C‑peptide testing highly reproducible and valuable for longitudinal monitoring of beta‑cell function, especially in patients with diabetes who may be on exogenous insulin therapy. Modern assays use either immunometric methods (e.g., ELISA or chemiluminescence) or liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) to ensure specificity and sensitivity, even in the presence of insulin antibodies or proinsulin fragments.

Physiological Roles of C‑Peptide: From Inert Byproduct to Bioactive Hormone

For decades following its discovery, C‑peptide was assumed to be biologically inert. However, a large body of experimental and clinical research has demonstrated that C‑peptide activates specific signaling pathways, binds to cell surface receptors, and modulates several key physiological processes. The most compelling evidence points to roles in microvascular regulation, inflammation modulation, neural protection, and renal preservation.

C‑Peptide and Endothelial Function

C‑peptide has been shown to stimulate endothelial nitric oxide synthase (eNOS) via activation of the PI3K/Akt pathway, leading to increased production of nitric oxide (NO). NO is a potent vasodilator that improves microvascular blood flow. In patients with type 1 diabetes, C‑peptide replacement has been associated with enhanced retinal and renal blood flow, reduced albuminuria, and improved nerve conduction velocity. These effects are dose‑dependent and appear to be mediated partly through binding to a specific G‑protein‑coupled receptor (GPCR) on endothelial cells. Recent work has identified the orphan receptor GPR146 as a candidate C‑peptide receptor, though definitive proof awaits further validation.

Neuroprotective Effects

Diabetic neuropathy is a common and debilitating complication. C‑peptide has demonstrated neuroprotective properties in both in vitro and in vivo models. It enhances Na⁺/K⁺‑ATPase activity in peripheral nerves, reduces oxidative stress, and promotes the release of nerve growth factors. Clinical trials using C‑peptide infusion in patients with type 1 diabetes have shown significant improvements in sensory nerve function, pain scores, and nerve fiber regeneration. For instance, the randomized, double‑blind, placebo‑controlled C‑Peptide in Diabetic Neuropathy Study (Ekberg et al., 2016) demonstrated that 12 weeks of subcutaneous C‑peptide infusion increased intraepidermal nerve fiber density and reduced neuropathic pain. These findings suggest that C‑peptide deficiency contributes directly to the development and progression of diabetic neuropathy.

Anti‑Inflammatory and Renal Actions

Chronic low‑grade inflammation is a hallmark of diabetes. C‑peptide suppresses the activation of nuclear factor‑kappa B (NF‑κB), reduces the expression of pro‑inflammatory cytokines (e.g., TNF‑α, IL‑6), and inhibits leukocyte‑endothelial adhesion. In the kidney, C‑peptide has been shown to attenuate mesangial cell proliferation and extracellular matrix accumulation—early events in diabetic nephropathy. Experimental models of diabetic kidney disease have also reported that C‑peptide reduces podocyte apoptosis and preserves slit diaphragm integrity. These anti‑inflammatory and antifibrotic effects add to the rationale for therapeutic C‑peptide administration.

Metabolic and Anti‑Apoptotic Effects on Beta‑Cells

Emerging evidence suggests that C‑peptide may act in an autocrine or paracrine manner to protect beta‑cells from apoptosis induced by high glucose, cytokines, or oxidative stress. In isolated human islets, C‑peptide exposure upregulates anti‑apoptotic proteins such as Bcl‑2 and suppresses caspase‑3 activation. This could have implications for preserving residual beta‑cell mass in early type 1 diabetes, though clinical confirmation is still needed.

Clinical Significance of C‑Peptide Testing

C‑peptide measurement is a cornerstone of the endocrine evaluation in patients with diabetes, hypoglycemia, and other pancreatic disorders. The test is performed on blood (serum or plasma) or on a 24‑hour urine collection, with results interpreted in conjunction with simultaneous glucose levels. Stimulated C‑peptide (e.g., after a mixed meal or glucagon injection) provides a more robust assessment of beta‑cell reserve than fasting samples alone.

Differentiating Type 1 and Type 2 Diabetes

In patients presenting with hyperglycemia, a fasting C‑peptide level can help distinguish autoimmune type 1 diabetes from insulin‑resistant type 2 diabetes. Low or undetectable C‑peptide (typically <0.2 nmol/L) indicates little or no endogenous insulin production, supporting a diagnosis of type 1 diabetes, latent autoimmune diabetes of adults (LADA), or secondary diabetes due to pancreatic damage. In contrast, normal or elevated fasting C‑peptide levels (>0.3–0.6 nmol/L) with hyperglycemia suggest insulin resistance and are characteristic of type 2 diabetes or monogenic forms such as MODY. The American Diabetes Association's classification guidelines emphasize the utility of C‑peptide in ambiguous presentations, especially when GAD antibody testing is equivocal.

Assessing Residual Beta‑Cell Function

Even after the diagnosis of type 1 diabetes, many patients retain some beta‑cell function for months or years. Measuring C‑peptide provides an objective way to quantify this residual capacity, which is associated with lower rates of severe hypoglycemia, better glycemic control, and reduced risk of long‑term complications. Preservation of stimulated C‑peptide is a key endpoint in clinical trials of immunotherapies (e.g., anti‑CD3 antibodies like teplizumab, CTLA4‑Ig like abatacept) aimed at halting autoimmune beta‑cell destruction. The Type 1 Diabetes TrialNet consortium routinely uses C‑peptide AUC after mixed‑meal tolerance tests as a surrogate endpoint.

Evaluation of Hypoglycemia

C‑peptide testing is essential in the workup of hypoglycemia, particularly when insulin‑induced hypoglycemia is suspected. In a patient with low plasma glucose (<3.0 mmol/L), a high C‑peptide level together with high insulin indicates endogenous hyperinsulinism—most commonly due to an insulinoma or sulfonylurea use. A suppressed C‑peptide (<0.2 nmol/L) with high insulin suggests exogenous insulin administration, including surreptitious use or factitious disorder. In insulin autoimmune syndrome (Hirata’s disease), C‑peptide levels are elevated while insulin antibodies cause misleading high insulin levels; free C‑peptide measurement helps clarify. Urinary C‑peptide measurement can also be useful for documenting chronic endogenous hyperinsulinemia over 24 hours.

Use in Pregnancy and Gestational Diabetes

In pregnancy, beta‑cell function changes dynamically. C‑peptide measurement can help differentiate gestational diabetes mellitus (GDM) from pre‑existing type 2 diabetes or monogenic diabetes. Women with GDM often have elevated fasting C‑peptide due to insulin resistance, while those with type 1 diabetes have low levels. However, pregnancy‑specific reference ranges are not well‑established, and renal clearance changes complicate interpretation.

C‑Peptide Testing: Practical Considerations and Pitfalls

To obtain reliable results, proper patient preparation and sample handling are critical. Fasting samples are preferred for baseline assessment, while a stimulated C‑peptide measurement (e.g., after a mixed meal or glucagon stimulation) provides a more robust test of beta‑cell reserve. The glucagon stimulation test (1 mg IV) with C‑peptide at 6 minutes remains a standard research tool.

Reference Ranges and Interpretation

Normal fasting C‑peptide levels vary by laboratory but generally fall between 0.3 and 1.0 nmol/L (0.9–3.0 ng/mL). Post‑stimulation levels can rise several‑fold. Interpretations must account for renal function, as impaired clearance can elevate C‑peptide levels. The simultaneous plasma glucose concentration is essential: a low C‑peptide with low glucose is appropriate; a high C‑peptide with low glucose is pathologic.

For more precise estimates, some laboratories use the C‑peptide‑to‑glucose ratio or calculate the HOMA‑Beta index (which uses fasting C‑peptide and glucose). These measures help quantify beta‑cell function across the spectrum of glucose tolerance. In insulin‑resistant states, the C‑peptide level may be disproportionately high relative to glucose.

Limitations and Pitfalls

  • Renal impairment: Accumulation of C‑peptide in chronic kidney disease can produce falsely elevated levels. In patients with eGFR <30 mL/min, urinary C‑peptide is unreliable; serum C‑peptide must be interpreted with caution.
  • Antibody interference: Insulin antibodies (e.g., from exogenous insulin therapy) can bind proinsulin and cause cross‑reactivity in some C‑peptide assays. Modern double‑antibody immunoassays and LC‑MS/MS minimize this issue.
  • Exogenous insulin: Exogenous insulin does not contain C‑peptide, so a low C‑peptide with high immunoreactive insulin suggests exogenous source. However, certain insulin analogs (e.g., glargine) may produce metabolites that interfere rarely.
  • Preanalytical variables: Hemolysis, delayed separation, and improper storage can degrade C‑peptide. Samples should be centrifuged within 30 minutes and stored at –20°C if not assayed promptly.
  • Partial beta‑cell destruction: In LADA or slowly progressive type 1 diabetes, C‑peptide may be low but detectable, requiring dynamic testing to unmask.

Therapeutic Potential of C‑Peptide in Endocrinology

Beyond its diagnostic use, C‑peptide is being investigated as a therapeutic agent to prevent or reverse diabetic complications. Several small‑scale clinical studies have demonstrated that subcutaneous infusion of C‑peptide (at doses that produce physiological concentrations) can improve renal function, nerve conduction, and vascular reactivity in patients with type 1 diabetes. The pivotal randomized, double‑blind, placebo‑controlled C‑Peptide in Diabetic Neuropathy Study showed significant improvements in nerve fiber density and sensory symptoms after 12 weeks of treatment, as noted earlier.

Other research has explored combining C‑peptide with insulin therapy, with promising results for cardiovascular autonomic neuropathy. In a 6‑month trial, C‑peptide supplementation improved heart rate variability and reduced QT dispersion. Although large‑scale phase III trials are still pending, the safety profile of C‑peptide appears excellent, and no serious adverse effects have been reported. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) continues to support studies on C‑peptide replacement, and a phase II trial is currently evaluating oral C‑peptide mimetics.

Future Directions in Research

Current research is converging on several frontiers:

  • Structural analogs: Development of C‑peptide analogs with improved stability, resistance to enzymatic degradation, and higher receptor affinity. Small‑molecule agonists of the putative C‑peptide receptor are also in preclinical stages.
  • Long‑acting formulations: Once‑weekly or depot preparations to eliminate the need for continuous subcutaneous infusion, which is currently impractical for routine use.
  • Combination therapies: Using C‑peptide alongside SGLT2 inhibitors or GLP‑1 receptor agonists to amplify renoprotective and neuroprotective effects, possibly through complementary mechanisms.
  • Biomarker discovery: C‑peptide degradation products (e.g., C‑peptide fragment 31–63) as novel markers of diabetic complications, potentially predicting nephropathy progression earlier than albuminuria.
  • Non‑diabetic applications: C‑peptide is being investigated in conditions with insulin resistance and microvascular dysfunction, such as the metabolic syndrome, Alzheimer’s disease, and polycystic ovary syndrome (PCOS). Preliminary data suggest that C‑peptide may improve endothelial function in PCOS‑related microvascular disease.

As our understanding of C‑peptide signaling deepens—including identification of the elusive C‑peptide receptor and downstream effectors—new avenues for therapeutic targeting will emerge. The Endocrine Society has highlighted C‑peptide as an “underappreciated hormone” with potential beyond diabetes, and the Endocrine Society’s diabetes resources now include dedicated sections on C‑peptide physiology.

Conclusion

C‑peptide has evolved from a passive marker of insulin secretion to a biologically active peptide with genuine therapeutic promise. Its measurement is indispensable for the accurate classification of diabetes, evaluation of hypoglycemia, and monitoring of beta‑cell function in clinical trials. Meanwhile, the accumulating evidence for C‑peptide’s vascular, neural, and anti‑inflammatory effects offers hope for novel interventions that could reduce the burden of diabetic complications. With ongoing research and technological advances—including long‑acting analogs and receptor‑based drug design—C‑peptide is likely to remain at the forefront of endocrinology, both as a diagnostic tool and as a potential treatment. For further reading, consult recent reviews in PubMed and the clinical practice guidelines from the American Diabetes Association.